Loading
PDBj
MenuPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

7NI1

CRYSTAL STRUCTURE OF NATIVE HUMAN MYELOPEROXIDASE IN COMPLEX WITH CPD 9

Summary for 7NI1
Entry DOI10.2210/pdb7ni1/pdb
DescriptorMyeloperoxidase, alpha-D-mannopyranose-(1-3)-beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-[alpha-L-fucopyranose-(1-6)]2-acetamido-2-deoxy-beta-D-glucopyranose, CHLORIDE ION, ... (10 entities in total)
Functional Keywordsoxidoreductase, complex, inhibitor
Biological sourceHomo sapiens (Human)
More
Total number of polymer chains4
Total formula weight135738.21
Authors
Sjogren, T.,Inghardt, T. (deposition date: 2021-02-11, release date: 2022-02-23, Last modification date: 2024-11-13)
Primary citationInghardt, T.,Antonsson, T.,Ericsson, C.,Hovdal, D.,Johannesson, P.,Johansson, C.,Jurva, U.,Kajanus, J.,Kull, B.,Michaelsson, E.,Pettersen, A.,Sjogren, T.,Sorensen, H.,Westerlund, K.,Lindstedt, E.L.
Discovery of AZD4831, a Mechanism-Based Irreversible Inhibitor of Myeloperoxidase, As a Potential Treatment for Heart Failure with Preserved Ejection Fraction.
J.Med.Chem., 65:11485-11496, 2022
Cited by
PubMed Abstract: Myeloperoxidase is a promising therapeutic target for treatment of patients suffering from heart failure with preserved ejection fraction (HFpEF). We aimed to discover a covalent myeloperoxidase inhibitor with high selectivity for myeloperoxidase over thyroid peroxidase, limited penetration of the blood-brain barrier, and pharmacokinetics suitable for once-daily oral administration at low dose. Structure-activity relationship, biophysical, and structural studies led to prioritization of four compounds for in-depth safety and pharmacokinetic studies in animal models. One compound (AZD4831) progressed to clinical studies on grounds of high potency (IC, 1.5 nM ) and selectivity (>450-fold thyroid peroxidase ), the mechanism of irreversible inhibition, and the safety profile. Following phase 1 studies in healthy volunteers and a phase 2a study in patients with HFpEF, a phase 2/3 efficacy study of AZD4831 in patients with HFpEF started in 2021.
PubMed: 36005476
DOI: 10.1021/acs.jmedchem.1c02141
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (2.11 Å)
Structure validation

237423

数据于2025-06-11公开中

PDB statisticsPDBj update infoContact PDBjnumon